Status:
COMPLETED
Immune Response to Influenza Vaccine in ESRD Patients
Lead Sponsor:
Mahidol University
Collaborating Sponsors:
Bhumirajanagarindra Kidney Institute, Thailand
Ministry of Health, Thailand
Conditions:
Immunology
Nephrology
Eligibility:
All Genders
Phase:
NA
Brief Summary
On-line hemodiafiltration (HDF) clears more azotaemic toxins compared to high-flux hemodialysis (HD). The response to vaccination is impaired in dialysis patients. We aimed to study the immune respons...
Eligibility Criteria
Inclusion
- \- ESRD patients aged 18 years or older, who had been treated for more than one month of either thrice weekly on-line hemodiafiltration (HDF) or conventional high flux hemodialysis (HD), with a session dialyzer urea clearance (Kt/V urea) of 1.2 and greater, with a convection volume target of 20 L/session for the HDF group
Exclusion
- Had received any vaccination within the previous four weeks, or influenza vaccination within six months
- Patient who reported upper respiratory tract symptoms within three days prior to the study vaccination
- A history of allergy to influenza vaccine or egg
- Thrombocytopenia
- In receipt of immunosuppressant medications, chemotherapy, or had immunodeficiency
Key Trial Info
Start Date :
August 25 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 20 2018
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04122222
Start Date
August 25 2016
End Date
July 20 2018
Last Update
October 10 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.